» Articles » PMID: 10961882

Urokinase Mediates Fibrinolysis in the Pulmonary Microvasculature

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2000 Aug 29
PMID 10961882
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The role of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in fibrinolysis remains unsettled. The contribution of uPA may depend on the vascular location, the physical properties of the clot, and its impact on tissue function. To study the contribution of urokinase within the pulmonary microvasculature, a model of pulmonary microembolism in the mouse was developed. Iodine 125 ((125)I)-labeled fibrin microparticles injected intravenously through the tail vein lodged preferentially in the lung, distributing homogeneously throughout the lobes. Clearance of (125)I-microemboli in wild type mice was rapid and essentially complete by 5 hours. In contrast, uPA(-/-) and tissue-type plasminogen activator tPA(-/-) mice, but not uPAR(-/-) mice, showed a marked impairment in pulmonary fibrinolysis throughout the experimental period. The phenotype in the uPA(-/-) mouse was rescued completely by infusion of single chain uPA (scuPA). The increment in clot lysis was 4-fold greater in uPA(-/-) mice infused with the same concentration of scuPA complexed with soluble recombinant uPAR. These data indicate that uPA contributes to endogenous fibrinolysis in the pulmonary vasculature to the same extent as tPA in this model system. Binding of scuPA to its receptor promotes fibrinolytic activity in vivo as well as in vitro. The physical properties of fibrin clots, including size, age, and cellular composition, as well as heterogeneity in endothelial cell function, may modify the participation of uPA in endogenous fibrinolysis. (Blood. 2000;96:1820-1826)

Citing Articles

Elevated international normalized ratio contributes to poor prognosis in patients with traumatic lung injury.

Lin Q, Peng E, Deng X, Song X, Zhong L, He L Front Med (Lausanne). 2024; 11:1426999.

PMID: 39156692 PMC: 11327037. DOI: 10.3389/fmed.2024.1426999.


Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor.

Zhu R, Liu T, Liu F Front Pharmacol. 2022; 13:754271.

PMID: 36034808 PMC: 9411529. DOI: 10.3389/fphar.2022.754271.


MicroRNA 449a can Attenuate Protective Effect of Urokinase Against Pulmonary Embolism.

Zhu R, Qi W, Liu T, Liu F Front Pharmacol. 2022; 13:713848.

PMID: 35571119 PMC: 9095938. DOI: 10.3389/fphar.2022.713848.


Targeting repair of the vascular endothelium and glycocalyx after traumatic injury with plasma and platelet resuscitation.

Barry M, Pati S Matrix Biol Plus. 2022; 14:100107.

PMID: 35392184 PMC: 8981767. DOI: 10.1016/j.mbplus.2022.100107.


Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.

Kattula S, Sang Y, de Ridder G, Silver A, Bouck E, Cooley B J Thromb Haemost. 2021; 19(12):2997-3007.

PMID: 34431201 PMC: 8605765. DOI: 10.1111/jth.15510.